InterContinental Taipei’s debut beside the Taipei Dome reflects a vision of luxury rooted in local culture, community, and the city’s evolving identity. With the philosophy “In Taipei, for Taipei,” the hotel aims to become part of the city’s next chapter rather than simply another landmark within it.
Microsoft’s latest Work Trend Index highlights the rise of “Frontier Firms,” where AI agents are becoming part of everyday workflows and reshaping how organizations structure work, productivity, and talent. As human–agent collaboration accelerates, businesses are moving beyond AI experimentation toward new models of digital labor, strategic roles, and AI-powered growth.
Amway’s global momentum in healthspan innovation helped drive $7.3 billion in 2025 sales, while Taiwan strengthened its role as a regional powerhouse with seven consecutive years of growth. Through product innovation, entrepreneurial opportunity, and long-term community engagement, Amway Taiwan continues to build on its 40-plus years of local impact.
Innovative medicines and vaccines play a vital role in improving public health, extending healthy lifespans, and strengthening national resilience. By recognizing their long-term clinical, social, and economic value, healthcare systems can better support future breakthroughs and broader patient access.
Roche underscores its long-term commitment to Taiwan’s Healthy Taiwan vision through sustained R&D investment, clinical trials, and real-world data supporting precision medicine. By advancing patient access and advocating for value-based healthcare, Roche aims to help Taiwan build a more innovation-friendly and sustainable biomedical ecosystem.
Pfizer Taiwan’s latest national honors highlight its continued role in advancing vaccine innovation, oncology treatment, and Taiwan’s broader public health resilience.
Herbalife Taiwan is building trust through transparent regulatory engagement, distributor education, and compliance systems spanning product quality, ethics, and consumer protection.
Novartis Taiwan is working with NHIA, medical societies, and healthcare partners to strengthen ASCVD prevention and care through clearer clinical pathways, earlier follow-up, and more consistent cholesterol management. The initiative reflects Taiwan’s growing focus on practical, cross-sector approaches to chronic disease management under the Healthy Taiwan vision.
Johnson & Johnson Taiwan is advancing patient access, precision diagnosis, and coordinated care to support the Healthy Taiwan vision and help more patients benefit from innovation earlier.
Novo Nordisk Taiwan is reframing obesity from weight loss to long-term health, emphasizing prevention, early intervention, and collaboration across Taiwan’s healthcare system. Through awareness, screening, and employee support, the company is helping advance a broader approach to metabolic health.
